3-D Matrix (7777) AI Stock Analysis

• Market Cap: $34.74B
• Dividend Yield: N/A
• Average Volume (3M): 4.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 45.67%
• EPS Growth: 29.44%
• Country: JP
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 6.89
• Shares Outstanding: 120,212,760
• 10 Day Avg. Volume: 2,399,770
• 30 Day Avg. Volume: 4,782,760
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 4.48
• Enterprise Value/Gross Profit: 6.27
• Enterprise Value/Ebitda: -94.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ¥289.00 ▼(-3.34% Downside)

The overall stock score reflects significant financial challenges, including high leverage and consistent losses, which are the most impactful factors. Technical analysis provides some positive signals, but valuation concerns due to negative profitability weigh heavily on the score.

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was founded in 2004 and is based in Tokyo, Japan.

How the Company Makes Money

3-D Matrix generates revenue primarily through the sale of its biomaterials and hydrogel products to hospitals, research institutions, and pharmaceutical companies. The company has established key partnerships with medical device manufacturers and research organizations, allowing it to leverage collaborative projects and co-development agreements. Additionally, revenue is supplemented by licensing agreements for its proprietary technologies, which provide a continuous stream of income as well as potential royalties from future product developments. The company may also engage in government and private grants for research and development, further contributing to its earnings.

3-D Matrix Financial Statement Overview

Summary

3-D Matrix faces significant financial challenges, with consistent losses and high leverage. While there is some revenue growth, profitability and cash flow remain areas of concern. The company needs to focus on reducing costs, improving operational efficiency, and managing debt to enhance financial stability and performance.

Income Statement

The company has shown some revenue growth over the years, with a 4.05% increase in the latest period. However, profitability remains a significant concern, with negative net profit margins and EBIT margins indicating ongoing operational challenges. The gross profit margin is relatively healthy at 63.81%, but the consistent net losses highlight the need for improved cost management and revenue generation.

Balance Sheet

The balance sheet reveals high leverage, with a debt-to-equity ratio of 1.33, indicating significant reliance on debt financing. The return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is low, suggesting potential financial instability and risk in meeting long-term obligations.

Cash Flow

Cash flow analysis shows negative operating cash flow, which is a concern for sustainability. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses. However, the negative free cash flow growth rate and operating cash flow coverage ratio highlight liquidity challenges and the need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.66B	6.93B	4.59B	2.31B	1.51B	1.02B
Gross Profit	4.76B	4.42B	3.09B	1.29B	661.01M	304.91M
EBITDA	-317.43M	-2.40B	59.13M	715.00M	843.00M	638.00M
Net Income	-949.00M	-2.50B	-255.50M	-2.45B	-1.89B	-2.01B
Balance Sheet
Total Assets	7.04B	6.51B	5.89B	5.83B	5.61B	3.51B
Cash, Cash Equivalents and Short-Term Investments	1.98B	1.58B	1.36B	1.17B	2.85B	1.14B
Total Debt	3.20B	2.94B	4.17B	4.37B	3.67B	1.46B
Total Liabilities	4.40B	4.30B	5.53B	5.30B	4.15B	1.85B
Stockholders Equity	2.64B	2.22B	353.31M	524.77M	1.46B	1.66B
Cash Flow
Free Cash Flow	0.00	-1.73B	-1.90B	-4.60B	-2.92B	-3.28B
Operating Cash Flow	0.00	-1.71B	-1.90B	-4.59B	-2.90B	-3.25B
Investing Cash Flow	0.00	-33.30M	-29.76M	-81.50M	-79.86M	-160.32M
Financing Cash Flow	0.00	2.01B	2.06B	2.96B	4.66B	3.46B

3-D Matrix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 299.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Positive. The current price of 299 is above the 20-day moving average (MA) of 289.30, above the 50-day MA of 269.92, and above the 200-day MA of 190.50, indicating a bullish trend. The MACD of 6.78 indicates Negative momentum. The RSI at 55.08 is Neutral, neither overbought nor oversold. The STOCH value of 85.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7777.

3-D Matrix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5187	―	¥9.35B	12.53	―	3.63%	3.38%	88.65%
6678	―	¥16.16B	15.75	―	3.59%	-8.07%	-38.21%
7963	―	¥9.06B	11.80	―	1.90%	9.07%	43.42%
7792	―	¥13.37B	10.65	―	2.87%	12.36%	38.55%
7600	―	¥13.54B	―	―	2.92%	4.84%	-148.94%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7777	―	$34.74B	-31.75	-49.32%	―	45.67%	29.44%

3-D Matrix Corporate Events

3-D Matrix and Harvard Achieve Breakthrough in Cardiac Regenerative Therapy

3-D Matrix, Ltd. has achieved a significant breakthrough in cardiac regenerative therapy through its collaborative research with Harvard University, which was published in the journal Science. The study demonstrated that the company’s self-assembling peptide, RADA16, can suppress arrhythmogenic automaticity in iPSC-derived cardiomyocytes and enhance their integration with host cardiac tissue, potentially accelerating the practical application of iPSC-based therapies for heart disease and advancing regenerative medicine for other tissues requiring vascularization.

The most recent analyst rating on (JP:7777) stock is a Hold with a Yen339.00 price target. To see the full list of analyst forecasts on 3-D Matrix stock, see the JP:7777 Stock Forecast page.